Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Appili Therapeutics
Its shares trade on Toronto Stock Exchange under the ticker APLI.TO. It has been listed since 25 June 2019. In the fiscal year to 31 March 2026, it reported revenue of C$244,179 and a net loss of C$4.2m. At that date it held total assets of C$2.0m and shareholders' equity of −C$17.3m.
Appili Therapeutics, Inc. is a pharmaceutical company, which acquires and develops novel treatments targeting unmet needs in infectious disease. The company is headquartered in Halifax, Nova Scotia. The company went IPO on 2019-06-25. The firm is focused on the acquisition and development of treatments targeting infectious disease. The firm is focused on building and advancing adverse portfolio of anti-infective programs. The Company’s anti-infective portfolio includes ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir. The ATI-2307 is a clinical-stage antifungal candidate in development for severe and difficult-to-treat invasive fungal infections. The ATI-1701 is a vaccine candidate for tularemia. The ATI-1503 is a drug discovery program aimed at generating a class of antibiotics with broad spectrum activity against gram-negative superbugs. The ATI-1501 employs its taste-masked, oral-suspension technology with metronidazole for the patients with difficulty swallowing.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 25 Jun 2019
- Employees
- 11
- Website
- appilitherapeutics.com ↗
Leadership
Pay as last reported
- Dr. Armand BalboniChairman of the Board, since 2019C$60,000
- Dr. Don CillaPresident, Chief Executive Officer, Director, since 2020C$732,442
- Mr. Kenneth HowlingActing Chief Financial OfficerC$568,347
- Mr. Arthur BaranDirector - New Product DevelopmentC$346,170
- Dr. Carl GelhausDirector - Non-Clinical ResearchC$361,056
- Dr. Gary NaborsChief Development OfficerC$610,481
- Dr. Theresa MatkovitsLead Independent DirectorC$131,200
- Mr. Brian BloomIndependent Director, since 2015C$57,600
- Dr. Juergen FroehlichIndependent DirectorC$83,680
- Mr. Prakash GowdIndependent DirectorC$93,680
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Appili Therapeutics Inc has several strengths that contribute to its success. Firstly, the company has a strong portfolio of innovative and promising therapeutics in its pipeline, which indicates potential future growth. Secondly, Appili Therapeutics Inc has a dedicated and highly skilled research and development team that possesses extensive knowledge in infectious diseases, allowing the company to develop effective treatments in this specialized area. Lastly, the company has established collaborations and partnerships with reputable academic institutions and research organizations, enhancing its capabilities in terms of expertise and resources.
Weaknesses
- Despite its strengths, Appili Therapeutics Inc also faces certain weaknesses. One major weakness is its relatively small size and limited financial resources compared to larger pharmaceutical companies. This can pose challenges in terms of competing with larger players and scaling up operations. Additionally, being a relatively young company, Appili Therapeutics Inc may lack the brand recognition and reputation that more established pharmaceutical companies have, which can make it more difficult to gain trust and secure partnerships.
Opportunities
- Appili Therapeutics Inc operates in a favorable market with significant opportunities for growth. The increasing prevalence of infectious diseases and the urgent need for effective treatments provide a favorable environment for the company's product portfolio. Moreover, Appili Therapeutics Inc can leverage advancements in technology and data analytics to improve its research and development processes, making drug discovery more efficient and targeted. The company also has the opportunity to expand its market reach by exploring partnerships or collaborations with international pharmaceutical companies or government health organizations.
Threats
- Appili Therapeutics Inc must also address potential threats that could impact its operations and growth. One significant threat is the highly competitive nature of the pharmaceutical industry, with numerous companies vying for market share and limited resources. This can make it challenging for Appili Therapeutics Inc to differentiate itself and secure funding or attract investors. Additionally, regulatory hurdles and stringent approval processes can delay the commercialization of the company's therapeutics, increasing time and costs. Furthermore, unforeseen events such as global pandemics or economic downturns can disrupt healthcare systems and investment trends, negatively impacting Appili Therapeutics Inc's operations.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.